GlassScriptPhysician profile
Debbie L Stroop
NPI 1952418519
$9,198.41
in general payments reported to CMS, 2019-2025
48 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,008 · 2022: $1,787 · 2023: $2,074 · 2024: $1,920 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,403.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,790.76 | 2021-2025 | |
| Lilly USA, LLC | $1,127.54 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,033.91 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $587.07 | 2021-2025 | |
| Abbott Laboratories | $388.32 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Glaxosmithkline, LLC. | $369.29 | 2021-2025 | Trelegy Ellipta, Pediarix, Bexsero |
| Amgen INC. | $293.84 | 2021-2025 | Evenity, Krystexxa, Repatha |
| Esperion Therapeutics, INC. | $291.41 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $258.31 | 2021-2025 | Airsupra, Farxiga, Fasenra |
| Janssen Pharmaceuticals, INC | $168.65 | 2021-2024 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $127.50 | 2021-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.50 | 2022-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $114.46 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.04 | 2021-2025 | |
| Astellas Pharma US INC | $106.13 | 2021-2024 | Veozah |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Stroop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.